MaxCyte (NASDAQ:MXCT – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01, FiscalAI reports. The business had revenue of $6.50 million during the quarter, compared to analyst estimates of $6.51 million. MaxCyte had a negative net margin of 114.77% and a negative return on equity of 18.52%.
Here are the key takeaways from MaxCyte’s conference call:
- MaxCyte reiterated its 2026 revenue guidance of $30 million–$32 million, with low single-digit year-over-year growth expected in the second half as instrument placements recover and prior inventory and partner-program headwinds subside.
- The new enterprise-level Genentech partnership provides access to MaxCyte’s ExPERT GTx, electroporation, and SeQure technologies across multiple programs and development stages, potentially creating recurring license, platform-use, instrument, consumables, and milestone revenue.
- Commercial momentum for Vertex’s CASGEVY continued, with approximately $76 million in second-quarter sales and more than 100 patient treatment initiations; MaxCyte’s SPL-related revenue rose to $0.8 million from $0.3 million a year earlier.
- Management reported broad stabilization in instrument and processing-assembly demand, early traction for the DTx platform, and expects instrument revenue to be the primary growth driver in the second half; it also sees potential commercial launches from five partner programs over the next few years, mainly in 2027.
- Second-quarter revenue declined 15% year over year to $7.3 million, while core revenue fell 21%; gross margin also decreased to 77% from 82% and is expected to remain in the mid-70% range as instrument revenue represents a larger mix.
MaxCyte Price Performance
MXCT stock opened at $1.30 on Friday. The company has a market cap of $139.79 million, a P/E ratio of -3.95 and a beta of 1.48. MaxCyte has a 1 year low of $0.64 and a 1 year high of $1.86. The stock’s fifty day moving average price is $1.19 and its 200-day moving average price is $0.98.
Institutional Trading of MaxCyte
Analyst Upgrades and Downgrades
Several brokerages have issued reports on MXCT. Weiss Ratings lowered MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $5.00.
Check Out Our Latest Research Report on MXCT
About MaxCyte
MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.
See Also
- Five stocks we like better than MaxCyte
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
- Cerebras Sells Off After Earnings: Is This a Market Disconnection?
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
